3 completed, 1 terminated. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Co-ArgI-PEG: new trials by email Literature Review of Co-ArgI-PEG trials Research Report on Co-ArgI-PEG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency Pegzilarginase - Arginase I Deficiency, Hyperargininemia | Phase 3 | Terminated | Aeglea Biotherapeutics | 3 | 2023-04-04 | 2023-07-27 |
| A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency AEB1102 - Arginase I Deficiency, Hyperargininemia | Phase 2 | Completed | Immedica Pharma AB | 14 | 2017-12-07 | 2026-09-24 |
| A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency AEB1102 - Arginase I Deficiency, Hyperargininemia | Phase 1 / Phase 2 | Completed | Aeglea Biotherapeutics | 16 | 2016-06-01 | 2019-06-12 |
| A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Co-ArgI-PEG - Advanced Cancers | Phase 1 | Completed | Immedica Pharma AB | 76 | 2015-10-22 | 2026-08-06 |
Hyperargininemia (3)
Aeglea Biotherapeutics (2) · Immedica Pharma AB (2)
Canada (3) · United States (3) · Portugal (2) · United Kingdom (2)
Mattias Rudebeck, PhD MSc BMedSc (2) · Cortney Caudill (1) · Josie Gayton (1)